ONET TECHNOLOGIES teams up with ALGETA for ALPHARADIN commercialization

Developed by ALGETA SAS of Norway, ALPHARADIN is a highly targeted alpha-pharmaceutical, currently under clinical evaluation, which is intended to improve survival in patients with bone metastases from advanced cancer.

Andrew Kay, the President and CEO of ALGETA SAS of Norway, says: We are delighted that ONET and ALGETA are working together on the final stages of the commercial manufacturing process for ALPHARADIN to ensure that the product will be available to cancer patients with bone metastases, pending approval for this first-in-class alpha-pharmaceutical.

This contract is a clear milestone in the development of ONET TECHNOLOGIES UK Ltd (OTUK), the British subsidiary of ONET TECHNOLOGIES, and complements its strategy for expansion in the radiopharmaceutical market, to which ONET TECHNOLOGIES will bring its extensive experience.

ALPHARADIN is the lead product developed by ALGETA ASA, which is based in Oslo (Norway). The Scandinavian firm is one of Europe's leading cancer-research companies and specialises in targeted therapies based on its alpha-pharmaceutical technology. ALGETA selected OTUK for the final stages of the process, regarding the supply of a high-capacity, state-of-the-art production line for the manufacturing of sterilized ready-to-use products.

OTUK's overall scope of work for the production line includes design, supply, installation and testing. The contract is similar to work undertaken by ONET TECHNOLOGIES for other clients in this sector, and relies on OTUK's experience and expertise in the radiopharmaceutical market.